StreetInsider.com News Articles

Form 424B5 Sunshine Biopharma Inc.

Mon, 20 Jul 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260720/26790106.html

Form 424B5 Sunshine Biopharma Inc.

Mon, 20 Jul 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260720/26790106.html

Sunshine Biopharma sets up $4M at-the-market stock offering

Mon, 20 Jul 2026 16:28:56 -0400

Sunshine Biopharma, Inc. (NASDAQ: SBFM) entered into an at-the-market issuance sales agreement with Aegis Capital Corp. on July 20, 2026, allowing the company to sell up to $4,000,000 in common stock through the arrangement.

Under the agreement, Aegis Capital will act as exclusive sales agent, receiving a commission of 3.0% of gross proceeds from any shares sold. Sales may be conducted through the Nasdaq Capital Market or any other existing trading market for the company's common stock, using any method permitted under Rule 415(a)(4) of the Securities Act of 1933.

The company is not obligated to sell any shares, and the agent

Sunshine Biopharma sets up $4M at-the-market stock offering

Mon, 20 Jul 2026 16:28:56 -0400

The company is not obligated to sell any shares, and the agent

Form 8-K Sunshine Biopharma Inc. For: Jul 20

Mon, 20 Jul 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260720/26790006.html

Form 8-K Sunshine Biopharma Inc. For: Jul 20

Mon, 20 Jul 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260720/26790006.html

Sunshine Biopharma and University of Arizona Publish Significant New Research Findings

Mon, 20 Jul 2026 08:30:00 -0400

FORT LAUDERDALE, FL / ACCESS Newswire / July 20, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications today announced the publication of new research results in the Journal of Medicinal Chemistry. The published data demonstrate a novel PLpro inhibitor, MR1-114, with nanomolar potency in at least three variants of the SARS-CoV-2 virus in vitro. MR1-114 was found to be efficacious in a mouse model of SARS-CoV-2 infection by repeated oral administration. This peer-reviewed study marks an important milestone for Sunshine Biopharma

Sunshine Biopharma and University of Arizona Publish Significant New Research Findings

Mon, 20 Jul 2026 08:30:00 -0400

Form 8-K Sunshine Biopharma Inc. For: Jul 08

Fri, 10 Jul 2026 16:54:00 -0400

si-local-file:///var/storage/secattach/20260710/26757844.html

Form 8-K Sunshine Biopharma Inc. For: Jul 08

Fri, 10 Jul 2026 16:54:00 -0400

si-local-file:///var/storage/secattach/20260710/26757844.html

Form SCHEDULE 13G Sunshine Biopharma Inc. Filed by: Alta Partners LLC

Wed, 08 Jul 2026 18:06:00 -0400

si-local-file:///var/storage/secattach/20260708/26748524.html

Form SCHEDULE 13G Sunshine Biopharma Inc. Filed by: Alta Partners LLC

Wed, 08 Jul 2026 18:06:00 -0400

si-local-file:///var/storage/secattach/20260708/26748524.html

Sunshine Biopharma gets Canadian approval for generic Anastrozole

Thu, 25 Jun 2026 08:01:03 -0400

Sunshine Biopharma Inc. (NASDAQ: SBFM) has received Canadian regulatory approval for its generic Anastrozole 1mg tablets, the generic equivalent of the breast cancer drug Arimidex, according to a company press release.

Anastrozole is a non-steroidal aromatase inhibitor used to lower estrogen levels in the body, and is considered standard care for adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer.

The company said it anticipates the product will be ready to ship to Canadian pharmacies before the end of 2026. Sunshine Biopharma distributes drugs in Canada through its wholly owned subsidiary, Nora Pharma Inc.

"We are pleased to introduce Anastrozole oral tablets

Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Arimidex(R)

Thu, 25 Jun 2026 08:00:00 -0400

FORT LAUDERDALE, FL / ACCESS Newswire / June 25, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its generic Anastrozole tablets of 1mg for the Canadian market. Anastrozole is the generic equivalent of the brand name breast cancer drug, Arimidex^®.

Anastrozole is a highly prescribed non-steroidal aromatase inhibitor. It works by lowering estrogen levels in the body to slow down or reverse the growth of specific breast tumors. Anastrozole is standard care for the adjuvant

Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Arimidex(R)

Thu, 25 Jun 2026 08:00:00 -0400

Form DEF 14C Sunshine Biopharma Inc. For: Jun 08

Mon, 08 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260608/26617234.html

Form DEF 14C Sunshine Biopharma Inc. For: Jun 08

Mon, 08 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260608/26617234.html

Sunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto(R)

Mon, 01 Jun 2026 08:00:00 -0400

FORT LAUDERDALE, FL / ACCESS Newswire / June 1, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its generic Rivaroxaban tablets of 2.5mg, 10mg, 15mg and 20mg for the Canadian market. Rivaroxaban is the generic equivalent of the brand name anticoagulant, Xarelto^®.

Rivaroxaban is a direct oral anticoagulant prescribed to treat and prevent deep vein thrombosis and pulmonary embolism. It is also widely utilized to reduce the risk of stroke and systemic embolism in patients

Sunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto(R)

Mon, 01 Jun 2026 08:00:00 -0400

Form 8-K Sunshine Biopharma Inc. For: May 28

Fri, 29 May 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260529/26575083.html

Form 8-K Sunshine Biopharma Inc. For: May 28

Fri, 29 May 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260529/26575083.html

Form PRE 14C Sunshine Biopharma Inc. For: May 29

Fri, 29 May 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260529/26575120.html

Form PRE 14C Sunshine Biopharma Inc. For: May 29

Fri, 29 May 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260529/26575120.html

Sunshine Biopharma receives patent for coronavirus treatment compounds

Fri, 29 May 2026 08:01:59 -0400

Sunshine Biopharma Inc. (NASDAQ: SBFM) announced that the United States Patent and Trademark Office issued U.S. Patent No. 12,624,066 B2 for compounds designed to treat coronavirus infections. The patent covers small molecule inhibitors that target a viral enzyme called PLpro, which suppresses the human immune system during coronavirus infections.

The compounds were developed by Sunshine Biopharma scientists during the COVID-19 pandemic. The technology targets what the company describes as a highly conserved viral function, intended to remain effective as the virus mutates.

"The issuance of this patent is a major milestone for Sunshine Biopharma and a validation of our scientific strategy," said

Sunshine Biopharma Announces Issuance of U.S. Patent 12,624,066 B2 Covering Novel Coronavirus Treatment Technology

Fri, 29 May 2026 08:00:00 -0400

FORT LAUDERDALE, FL / ACCESS Newswire / May 29, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,624,066 B2, titled "Compounds and Methods for Treatment of Coronavirus Infection." The newly granted patent protects Sunshine Biopharma's proprietary therapeutic compounds designed to inhibit coronavirus replication.

The patent covers a series of small molecule inhibitors discovered and developed by Sunshine Biopharma scientists during the COVID-19 pandemic. These compounds target a